Trial Profile
Study of sofosbuvir/velpatasvir (SOF/VEL) combination for 12 weeks without ribavirin in patients with and without cirrhosis regardless of HCV genotype in real life
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2018
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 15 May 2018 New trial record
- 14 Apr 2018 Results (n=513) of mono-infected patients who completed SVR4 by Nov 1st presented at The International Liver Congress 2018